BVS vs. NVCR, LMAT, ENOV, CNMD, EYE, LQDA, CDRE, TNDM, AORT, and PLSE
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include NovoCure (NVCR), LeMaitre Vascular (LMAT), Enovis (ENOV), CONMED (CNMD), National Vision (EYE), Liquidia (LQDA), Cadre (CDRE), Tandem Diabetes Care (TNDM), Artivion (AORT), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry.
Bioventus vs. Its Competitors
NovoCure (NASDAQ:NVCR) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.
In the previous week, NovoCure had 5 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for NovoCure and 1 mentions for Bioventus. NovoCure's average media sentiment score of 0.66 beat Bioventus' score of 0.00 indicating that NovoCure is being referred to more favorably in the media.
NovoCure has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Bioventus has lower revenue, but higher earnings than NovoCure. Bioventus is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.
84.6% of NovoCure shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 6.3% of NovoCure shares are owned by insiders. Comparatively, 32.9% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
NovoCure received 447 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 62.98% of users gave NovoCure an outperform vote while only 62.00% of users gave Bioventus an outperform vote.
NovoCure presently has a consensus target price of $32.83, indicating a potential upside of 89.13%. Bioventus has a consensus target price of $14.33, indicating a potential upside of 113.61%. Given Bioventus' higher probable upside, analysts plainly believe Bioventus is more favorable than NovoCure.
Bioventus has a net margin of -7.11% compared to NovoCure's net margin of -25.93%. Bioventus' return on equity of 15.61% beat NovoCure's return on equity.
Summary
Bioventus beats NovoCure on 9 of the 17 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
This page (NYSE:BVS) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy BVS Stock Free BVS Stock Alerts